Cardiol Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Revenue	-	-	-	-	0.08	Upgrade
Gross Profit	-	-	-	-	0.08	Upgrade
Selling, General & Admin	20.3	26.26	15.56	22.37	27.87	Upgrade
Research & Development	14.02	14.01	14.22	18.96	10.87	Upgrade
Operating Expenses	34.32	40.28	29.79	41.34	38.74	Upgrade
Operating Income	-34.32	-40.28	-29.79	-41.34	-38.66	Upgrade
Interest & Investment Income	0.73	1.19	2.04	1.24	0.11	Upgrade
Currency Exchange Gain (Loss)	-1.18	2.14	-0.71	2.76	1.89	Upgrade
Other Non Operating Income (Expenses)	0.95	0.27	0.33	6.41	5.03	Upgrade
Pretax Income	-33.82	-36.68	-28.13	-30.93	-31.64	Upgrade
Net Income	-33.82	-36.68	-28.13	-30.93	-31.64	Upgrade
Net Income to Common	-33.82	-36.68	-28.13	-30.93	-31.64	Upgrade
Shares Outstanding (Basic)	87	72	64	63	43	Upgrade
Shares Outstanding (Diluted)	87	72	64	63	43	Upgrade
Shares Change (YoY)	21.55%	11.02%	3.13%	44.61%	44.77%	Upgrade
EPS (Basic)	-0.39	-0.51	-0.44	-0.49	-0.73	Upgrade
EPS (Diluted)	-0.39	-0.51	-0.44	-0.49	-0.73	Upgrade
Free Cash Flow	-23.88	-25.08	-25.24	-27.3	-23.55	Upgrade
Free Cash Flow Per Share	-0.28	-0.35	-0.39	-0.44	-0.55	Upgrade
Gross Margin	-	-	-	-	100.00%	Upgrade
Operating Margin	-	-	-	-	-49091.93%	Upgrade
Profit Margin	-	-	-	-	-40170.45%	Upgrade
Free Cash Flow Margin	-	-	-	-	-29904.22%	Upgrade
EBITDA	-34.28	-39.97	-29.59	-41.16	-38.44	Upgrade
D&A For EBITDA	0.04	0.31	0.2	0.18	0.22	Upgrade
EBIT	-34.32	-40.28	-29.79	-41.34	-38.66	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.